Since IPF is associated with a variety of pathways, including TGFβ1 and other tyrosine kinases pathways (PDGF, FGF and VEGF), The treatments for IPF require a multiple-targeting strategy, in which the TGFβ1 signalling is an essential pharmacological target. Here, VEGFA is linked to idiopathic pulmonary fibrosis.